Clinical Trial Update: C11-Sodium Acetate PET/CT Imaging Evaluation in Brain Glioma, Post Therapy Necrosis and Pseudo-progression [Phase 2, Phase 3]

View source ↗

Summary

A Phase 2/Phase 3 clinical trial evaluating C11-sodium acetate PET/CT imaging for brain glioma, post-therapy necrosis, and pseudo-progression has been withdrawn…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioma

Drugs mentioned

• 11C-sodium acetate (11C-sodium acetate)

Snippet

Sponsor: Phoenix Molecular Imaging | Conditions: Gliomas | Phase 2, Phase 3 | Status: WITHDRAWN